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Abstract
Anti-hepatitis C virus (HCV) cross-neutralizing human monoclonal antibodies, directed against conserved epitopes on
surface E2 glycoprotein, are central tools for understanding virus-host interplay, and for planning strategies for prevention
and treatment of this infection. Recently, we developed a research aimed at identifying these antibody specificities. The
characteristics of one of these antibodies (Fab e20) were addressed in this study. Firstly, using immunofluorescence and
FACS analysis of cells expressing envelope HCV glycoproteins, Fab e20 was able to recognize all HCV genotypes. Secondly,
competition assays with a panel of mouse and rat monoclonals, and alanine scanning mutagenesis analyses located the e20
epitope within the CD81 binding site, documenting that three highly conserved HCV/E2 residues (W529, G530 and D535)
are critical for e20 binding. Finally, a strong neutralizing activity against HCV pseudoparticles (HCVpp) incorporating
envelope glycoproteins of genotypes 1a, 1b, 2a, 2b and 4, and against the cell culture-grown (HCVcc) JFH1 strain, was
observed. The data highlight that neutralizing antibodies against HCV epitopes present in all HCV genotypes are elicited
during natural infection. Their availability may open new avenues to the understanding of HCV persistence and to the
development of strategies for the immune control of this infection.
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Introduction
The hepatitis C virus (HCV) infection is presently a major
public health problem, and nearly 3% of the world population is
persistently infected with this virus [1,2]. At least six major HCV
genotypes and more than 50 subtypes have been described based
on nucleotide diversity of the core, E1\E2, and NS5 regions
[3,4,5]. Moreover, HCV infection is characterized by high intra-
host variability, due to high mutation rate and replication activity
in vivo. As a direct consequence of this variability, each HCV-
infected patient harbours a population of related, but genetically
distinct viral variants. It is presently believed that HCV variability
strongly determines virus persistence in the infected hosts, allowing
its escape from the immune system [6,7,8] .
Despite almost two decades of studies, no vaccine is presently
available to prevent infection with this virus. Efforts aimed at
developing an anti-HCV vaccine have been hampered by the high
virus variability, the substantial lack of readily available animal
models, and the absence of clearly established in vitro correlates of
protective immunity. It is currently believed that CD4+ and CD8+
T-cell responses are central in the control of acute HCV infection.
Otherwise, the role of anti-HCV humoral response is still
controversial [9,10,11]. However, recent data have suggested that
neutralizing anti-HCV antibody responses may strongly influence
the natural course of HCV infection. In this context, an effective
immunization against HCV calls for induction of both robust T-
and B-cell responses. As far as the latter point is concerned, this
result is possible if new immunogens are designed, capable of
eliciting broadly reacting and neutralizing antibodies.
Recently, the availability of viral pseudotypes bearing surface
HCV glycoproteins (E1 and E2) has offered a reliable model
system to evaluate in vitro the anti-HCV neutralizing activity of
polyclonal sera and monoclonal antibodies. Using this approach, it
has been shown that neutralizing activity is detectable in sera from
a significant proportion of infected patients during primary and
persistent HCV infection [12,13], and that the presence of high
titres of neutralizing antibodies directed against conserved epitopes
may influence the virus-host interplay during all stages of the
infection [14,15,16,17,18]. In the last few years, we have used
phage-display to dissect the antibody response of HCV-infected
patients, searching for potentially cross-reactive Fabs directed
against HCV/E2. Using this approach, we have obtained several
cross-reactive anti-HCV/E2 human mAbs endowed with different
biological characteristics [19,20,21,22,23,24,25]. In the study
shown here, we evaluated the binding characteristics of a human
monoclonal Fab (named e20) that was able to bind E2
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glycoproteins of all tested genotypes. Notably, this Fab was able to
cross-neutralize HCVpp containing E1\E2 from different
genotypes.
Materials and Methods
Ethics Statement
Previous studies, that allowed the cloning of the human
monoclonal antibody used in this research, were approved by
the University Vita-Salute Ethical Committee. However, the
present study, not presenting experiments on animals, human
samples, or patients, and being based on a recombinant protein
expressed in a bacterial vector, did not specifically require a formal
adjunctive approval.
Analysis of the Binding Activity
The binding activity of anti-HCV/E2 monoclonal Fab e20 was
assayed using recombinant HCV/E2 proteins derived from
different genotypes. The following isolates were used: geno-
type 1a (isolate H77.20); 1b (UKN1B12.16); 2a (UKN2A.2.4);
2b (UKN2B2.8); 3 (UKN3A1.28c); 4 (UKN4.21.16); 5
(UKN5.15.11) and 6 (UKN6.5.8). In brief, human epithelial
kidney (HEK) 293T cells were transfected with 3 mg of pcDNA3.1
vector [5], an expression vector encoding surface glycoproteins of
the above listed HCV isolates [26]. After centrifugation, fixation
and permeabilization, the transfected cells were incubated with
e20 (10 mg/ml). After further washings, the cells were incubated
with a FITC-conjugated anti-human Fab monoclonal antibody,
and analysed by fluorescent microscopy and by FACS. Untrans-
fected cells and a human recombinant Fab (c33-3) specific for a
non-structural antigen of HCV (NS3) were also included in each
experiment as negative controls [27].
A mouse broadly cross-reactive monoclonal (AP33) was used to
analyze the transfection efficiency for each genotype. The
percentage of AP33-incubated sorted cells featuring a higher
fluorescence signal than untreated cells was comparable for all
different genotypes (approximately 70% of 10,000 cells analysed
by FACS).
The binding activity of e20 against the different genotypes was
then expressed as percentage of the reactivity observed on
genotype 1a (relative binding activity), measured by sorting for
each genotype the number of cells featuring a higher fluorescence
signal than cells without Fab. The fluorescence obtained using e20
on untransfected cells was subtracted as background.
Epitope Characterization: Competition ELISA
In order to map the e20 epitope, competition ELISA assays
were performed using a panel of well-characterized murine and rat
monoclonals (Table 1). Competition experiments were conducted
reciprocally, as previously described [19], using plates coated with
HCV/E2 of genotype 1a (4 mg/ml). In brief, Fab e20 was titrated
and used as probe at a concentration giving 50% of maximum
binding, whereas all competing mAbs were used at a saturating
concentration. In this case, a horse radish peroxidase (HRP)-
conjugated anti-human IgG Fab polyclonal was used to detect Fab
20 binding on HCV/E2. Alternatively, each mouse or rat
monoclonal was used as probe at a concentration giving 50% of
maximum binding, and Fab e20 was used at a saturating
concentration. In this case, HRP-conjugated anti-mouse or anti-
rat IgG polyclonals were used to detect the binding on HCV/E2.
Final results were determined as percent inhibition with the
following formula: percent inhibition = 1006 [(OD450 of probe
Fab alone2OD450 of probe Fab with competitor Fab)/OD450 of
probe Fab alone].
Epitope Characterization: Binding Experiments on Point-
Mutated HCV\E2 Clones
To define better the critical E2 residues involved in binding, the
reactivity of Fab e20 to a panel of alanine point-mutated H77-
derived HCV/E1-E2 (1a) clones [28] was determined. Five of
Table 1. Inhibition of human anti-HCV/E2 Fab e20 binding by
competing anti-HCV/E2 rat or mouse mAbs directed against
known regions of the antigen.
Competing mAbs HCV/e2 epitope e20
7/59 384–391 3
3/11 412–423 5
AP33 412–423 40
1/39 436–443 57
11/20 436–447 4
7/16b 436–447 5
H47 452–459 4
6/1a 464–471 2
6/41a 480–493 5
2/64a 524–531 32
9/75 528–535 76
6/53 544–551 4
H62 644–655 2
The results were confirmed in a reciprocal competition assay, using each mouse
and rat monoclonal as a probe. Data are expressed as % of inhibition.
doi:10.1371/journal.pone.0008254.t001
Figure 1. Binding activity of Fab e20 on E1E2 derived from
different HCV genotypes. The following strains were used: genotype
1a (isolate H77.20); 1b (UKN1B12.16); 2a (UKN2A.2.4); 2b (UKN2B2.8); 3
(UKN3A1.28c); 4 (UKN4.21.16); 5 (UKN5.15.11) and 6 (UKN6.5.8). The
broadly cross-reactive monoclonal AP33 was used to assess that the
efficiency of transfection was comparable for all different genotypes.
Binding activity for each genotype is expressed as percentage of the
reactivity observed on E1E2 of genotype 1a (H77 strain). The means and
standard errors of two replicate assays are reported.
doi:10.1371/journal.pone.0008254.g001
Neutralizing Anti-HCV Fab
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these mutants (W420A, Y527A, W529A, G530A, D535A)
completely inhibit HCV/E2 binding to CD81 also abrogating
the infectivity of HCV pseudoparticles [28] . Differences in e20
binding to wild type H77 and to each mutant were determined by
FACS, following the protocol described above. In this approach,
the ALP98 mouse mAb (directed against a linear epitope outside
the mutated regions) [29] was used to evaluate the expression level
of the mutated E1E2.
Neutralization Assays on HCV Pseudoparticles (HCVpp)
and on HCV Cell Culture Infectious Viral Particles (HCVcc)
The neutralizing activity of Fab e20 was tested using a HCV
pseudoparticle (HCVpp)-based neutralization assay, following
already described protocols [26]. In particular, Fab e20 neutral-
izing activity was tested against pseudoparticles derived from
murine leukemia virus (MLV) displaying unmodified and
functional full-length E1-E2 proteins representative of all the
major HCV genotypes. In brief, HEK293T cells were cotrans-
fected with the MLV Gag-Pol packaging vector, the MLV-
luciferase reporter gene, and the plasmid expressing HCV E1E2
from different genotypes. In all experiments, control particles
expressing vesicular stomatitis virus (VSV) G protein were used.
Two days after transfection, the medium containing HCVpp was
collected, clarified, filtered through a 0.45-mm-pore-size mem-
brane, and used for infection of Huh-7 cells. Three days following
infection, the cells were analyzed on a luminometer using the
Bright-Glo TM luciferase assay kit (Promega). For all genotypes,
but genotype 3 and genotype 6, the detected luminescence ranged
from 10,000 to 20,000 relative luminescence units (RLU). For the
neutralization assay, the HCVpp (10,000 RLU) were pre-
incubated with different concentrations of Fab e20. The anti-
HCV/NS3 Fab c33-3 was used as negative control.
The neutralizing activity of Fab e20 was also investigated using
the cell culture infectious HCV (HCVcc) system, based on HCV
genotype 2a strain JFH-1 [30,31]. The infectivity of JFH-1 in the
presence of different concentrations of Fab e20, and of the
negative-control Fab (c33-3) was determined by quantitative
reverse transcription-PCR, normalizing the viral RNA against
the RNA of a housekeeping gene (glyceraldehyde-3-phosphate
dehydrogenase)[32].
Results and Discussion
The HCV genome encodes a mutation prone polymerase,
resulting in the formation in vivo of a population of genetically
Figure 2. Residues recognized by Fab e20 on HCV/E2. (a) Reactivity of Fab e20 on a panel of mutated E1E2 glycoproteins derived from H77
strain. Binding activity, expressed as a percentage of the reactivity on wild type E1-E2 (H77 strain), is shown on the y axis; the mutated residues are
shown on the x axis. Fab e20 was tested at 10 mg/ml. The means and standard errors of two independent assays are reported. (b) HCV/E2 partial
sequence alignment of the HCV strains used in this study. The genotype of each strain is reported in brackets. Residues Y527, W529, G530 and D535
abrogating the binding to CD81 are depicted in red. Shaded grey boxes evidence the conserved residues recognized by e20.
doi:10.1371/journal.pone.0008254.g002
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related, but distinct variants. It is presently believed that the capacity
of the virus to mutate contributes, together with the high replication
rates, to the establishment of persistence. A hypervariable region
(HVR1) of the HCV E2 glycoprotein has been observed to be a
major determinant of isolate-specific neutralizing antibodies [33].
These antibodies provide, however, little protection against
infection, due to the continuous sequence evolution of HVR1
[33]. Otherwise, it has been observed that broadly neutralizing
antibodies are usually directed against highly conserved conforma-
tional epitopes of the E2 glycoprotein [21,22,24,34,35,36,37].
Fab e20 investigated in this study was able to bind HCV/E2
derived from all tested genotypes (Figure 1), indicating the highly
Figure 3. Neutralizing activity of Fab e20 using virus pseudoparticles (HCVpp). The following strains were used: genotype 1a UKN1A20.8
(a); E1E2 genotype 1b UKN1B5.23 (b); genotype 2a UKN2A1.2 (c); genotype 2b UKN2B1.1 (d); genotype 4 UKN4.21.16 (e). Data obtained from HCVpp
infection in the presence of different concentrations of c33-3 (negative control) and e20 are presented as a percentage of the infection detected in
the absence of antibody. The means and standard errors of two replicate assays are reported. HCVpp displaying genotype 3 (UKN3A1.28c) and
genotype 6 (UKN6.5.8) did not give consistent signals in repeated assays, and were therefore not evaluated. No neutralizing activity was observed
against genotype 5 (UKN5.15.11).
doi:10.1371/journal.pone.0008254.g003
Neutralizing Anti-HCV Fab
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conserved nature of its epitope. The wide cross-reactivity of Fab
e20 was also documented by immunoprecipitation of HCV/E2
on radiolabeled lysates from HEK293T cells expressing HCV
surface proteins of different genotypes (data not shown). The
broad cross-reactivity of Fab e20 prompted us to better
characterize its epitope on HCV/E2. Previous data had already
suggested that the epitope was conformationally constrained, as
the Fab failed to bind either denatured HCV/E2 or multiple
overlapping peptides encompassing the whole HCV/E2 se-
quence [23]. Moreover, Fab e20 did not show any reactivity in
ELISA to five different Maltose Binding Protein-HCV/E2 fusion
proteins ([E2a] - aa 384–444; [E2ab] - aa 384–512 [E2abc] - aa
384–583; [E2abcd] - aa 384–668 and [E2abcde] - aa 384–714)
(Methods S1 and Table S1), or to five HVR multiple antigenic
peptides [38] (MAP 291, MAP 313, MAP 442, MAP 455 and
MAP 1013) (Methods S1 and Table S2), which were specifically
recognized by some of the antibodies directed against linear
epitopes used in this study. These data confirmed that e20 is
directed against a conformational epitope which is retained only
in the full length HCV/E2.
In the competition assays, Fab e20 was strongly inhibited by 9/75,
a rat mAb recognizing the linear epitope 528–535 on HCV/E2
(Table 1) [39]. Fab e20 also competed with rat mAb 1/39 (436–443)
and, partially, with mouse mAb AP33 (412–423), the broadest cross-
reactive and cross neutralizing antibody described to date (Table 1)
[26,40]. The competition with mAb 9/75 was confirmed by the fact
that mutations at conserved positions 529, 530 and 535 on HCV/E2,
which are located within the epitope recognized by mAb 9/75 and
which are involved in the binding to CD81 [28], totally abrogated the
binding of e20 (Figure 2a). These data show that these residues, highly
conserved among different genotypes (Figure 2b), have a crucial role
Figure 4. Neutralizing activity of Fab e20 using the HCVcc
system (genotype 2a). The infectivity of JFH-1 in the presence of e20
and of negative-control Fab (c33-3) is presented as the viral RNA
quantity normalized against glyceraldehyde-3-phosphate dehydroge-
nase RNA, as determined by quantitative reverse transcription-PCR [32].
The means and standard errors of three replicate assays are reported.
doi:10.1371/journal.pone.0008254.g004
Table 2. Synopsis of published anti-HCV/E2 human monoclonals binding to all major HCV genotypes (1a, 1b, 2a, 2b, 3a, 4, 5, 6).
mAb Crucial residues on HCV/E2 (H77 strain) Neutralizing activity Assay format and genotype
Antibody
format References
e20 W529, G530, D535 7.5
HCVpp 1a
IgG1 Fab This paper
7.5
HCVpp 2a
1.6
HCVpp 4
,,1
HCVcc 2a
1:7 G523, W529, G530, D535 0.06
HCVcc 2a
whole IgG1 [35]
A8 G523, W529, G530, D535 0.56
HCVcc 2a
whole IgG1 [35]
CBH-5 C494, V497, G523, P525, G530, D535, N540, R614, H617, Y618,
P619, T621, F624
1.77
HCVpp 1b
whole IgG1 [37,42,43,50,51]
0.1
HCVpp 2a
13
HCVpp 2b
0.056
HCVcc 2a
0.04
HCVcc 2b
CBH-7 C494, V497, N540, W549, R614, H617, Y618, P619, T621, F624 25.58
HCVcc 2a
whole IgG1 [37,42,43,50,51]
1.3 HCVcc 2b
The E2 residues involved in the binding of each antibody are reported (those crucial for e20 binding are in bold and underlined). Only the concentrations giving 50%
neutralization (IC50) against HCV pseudoparticles (HCVpp) derived from different genotypes, or against HCV cell culture (HCVcc) strains, are reported. Punctual IC50
values are not available for mAbs 1:7 and A8 against HCVpp [35], and for CBH-5 and CBH-7 against HCVpp derived from genotypes 1a, 3a, 4, 5 and 6 [37,42,43,50,51]. E20
is the only monoclonal tested as Fab fragment.
doi:10.1371/journal.pone.0008254.t002
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in generating the epitope recognized by Fab e20, and further indicate
their importance in the production of anti-HCV/E2 broadly
neutralizing antibodies [24,26,34,36,41]. On the contrary, in spite
of the competition observed with AP33, mutations inside the AP33
epitope did not affect e20 binding, showing that the e20
conformational epitope does not contain the linear AP33 epitope,
and that the observed competition may be mediated by steric
hindrance, or by induced conformational changes of the antigen.
Fab e20 featured a potent neutralization activity against
HCVpp derived from genotype 1a, with an IC50 (Fab
concentration giving 50% neutralization) of 7.5 mg/ml
(Figure 3a), and derived from genotypes 2a and 4, with IC50
values of 7.5 mg/ml and 1.6 mg/ml, respectively (Figure 3c and
3e). Finally, e20 was able to inhibit, albeit to a lesser extent, the
infection of HCVpp 1b and 2b, with IC40 values of 15 mg/ml and
30 mg/ml, respectively (Fig. 3b and 3d). No neutralizing activity
was observed against genotype 5 (UKN5.15.11). Unfortunately, it
was not possible to perform the assay on genotypes 3 and 6, due to
the very low and not reproducible infectivity observed for these
genotypes [34]. Finally, the cross-neutralizing activity of e20 was
also investigated using the cell culture infectious HCV (HCVcc)
system based on HCV genotype 2a strain JFH-1 [30]. In this assay
Fab e20 showed an even stronger neutralizing activity, since at a
concentration as low as 1 mg/ml it was able to completely abrogate
the infectivity of HCVcc (Figure 4).
Overall, the data presented here highlight that broadly cross-
reactive and cross-neutralizing antibodies, as Fab e20, are
generated during the natural course of HCV infection, and that
they are directed against conserved epitopes on HCV/E2. We
have observed that Fab e20 is able to bind all of the HCV/E2
genotypes tested, including the most phylogenetically distant
genotype 2, and that it recognizes an epitope centred on three
crucial residues (W529, D530 and G535). These residues, highly
conserved among different HCV genotypes, are involved in E2
binding to the CD81, a possible co-receptor of HCV, and are
recognized by other neutralizing antibodies [24,34,35,37]. More
in details, Fab e20 is one of the few human monoclonals
described to date as capable of binding all major HCV
genotypes. Three of these monoclonals (1:7; A8 and CBH-5)
share with e20 the residues D530 and G535 (1:7 and A8 share
also W529); however, although not easily comparable because
tested in different settings, they feature different neutralizing
activities against different genotypes, evidencing that other
residues outside those studied may play a role [42,43]. The main
features of these broadly reacting antibodies, all tested as whole
IgG1, are reported in Table 2 and are compared to the
characteristics of e20, which has been tested as Fab fragment.
An intriguing aspect is the fact that Fab e20, although
recognizing genotype 5 E2 on transfected cells, was not able to
neutralize in our hands HCVpp obtained with the same
glycoprotein. In theory, this can be due (i) to low sensitivity of
the HCVpp neutralization assay [37] or, (ii) to the role played by
residues located outside the CD81 binding site and not tested in
the mutants panel, but possibly important for the neutralizing
activity of e20 against genotype 5 [44].
Finally, it is important to note that e20 biological activity was
tested using the antibody as a Fab fragment, and that its activity may
increase in the whole immunoglobulin format [45]. That may result
in increased neutralizing potency not only to genotypes 1a, 2a and
4, but also to genotypes 1b and 2b. Moreover, the better knowledge
of the broadly neutralizing epitopes on HCV/E2 glycoprotein, and
the availability of a panel of antibodies with broadly neutralizing
characteristics, similar to those observed for e20, may also allow the
use of a balanced combination of neutralizing antibodies, thus
resulting in a synergic enhancement of the overall neutralizing
activity (as already observed with HIV) [46,47,48,49].
Supporting Information
Table S1 Binding of e20 Fab to maltose binding protein-E2
fusion constructs (O.D.450). The human Fab C33 directed against
HCV/NS3 was used as negative control; mouse Mabs 7/59, 7/
16b and 6/53 were used as positive controls.
Found at: doi:10.1371/journal.pone.0008254.s001 (0.03 MB
DOC)
Table S2 Binding of human anti-HCV/E2 Fab e20 to multiple
antigenic peptides (MAP) (O.D.450). The sequence of each MAP
is reported. The human Fab C33 was used as negative control;
mouse Mabs 7/59 and 9/27 were used as positive controls.
Found at: doi:10.1371/journal.pone.0008254.s002 (0.03 MB
DOC)
Methods S1 Binding of human anti-HCV/E2 Fab e20 to
Maltose Binding Protein (MBP)-HCV/E2 fusion proteins. Binding
of human anti-HCV/E2 Fab e20 to Hypervariable region 1
(HVR1) multiple antigenic peptides.
Found at: doi:10.1371/journal.pone.0008254.s003 (0.02 MB
DOC)
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